Carnegie Investment Counsel’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-7,190
Closed -$200K – 484
2023
Q3
$200K Sell
7,190
-175
-2% -$5.72K 0.01% 473
2023
Q2
$251K Sell
7,365
-190
-3% -$5.97K 0.01% 450
2023
Q1
$227K Sell
7,555
-2,179
-22% -$67.5K 0.01% 473
2022
Q4
$275K Sell
9,734
-205
-2% -$6.51K 0.01% 437
2022
Q3
$327K Sell
9,939
-100
-1% -$3.67K 0.02% 392
2022
Q2
$316K Sell
10,039
-1,209
-11% -$42.3K 0.01% 395
2022
Q1
$517K Sell
11,248
-850
-7% -$40.5K 0.02% 343
2021
Q4
$741K Sell
12,098
-11,624
-49% -$804K 0.02% 312
2021
Q3
$1.77M Buy
23,722
+5,074
+27% +$426K 0.07% 194
2021
Q2
$1.73M Buy
18,648
+2,727
+17% +$232K 0.07% 201
2021
Q1
$1.41M Buy
15,921
+12,561
+374% +$1.25M 0.06% 213
2020
Q4
$313K Buy
+3,360
New +$268K 0.01% 354

Other funds holding ARKG

Carnegie Investment Counsel's ARKG Position: Q4 2023 in Review

Carnegie Investment Counsel sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2023, closing a stake of 7,190 shares — an estimated $200K sold.

Carnegie Investment Counsel first reported a position in ARKG in Q4 2020 and held it in 12 quarters. The position peaked at $1.77M in Q3 2021. 300 funds tracked by Wall St. Rank hold ARKG as of Q4 2023.

  • Carnegie Investment Counsel reported no remaining ARK Genomic Revolution ETF position as of Q4 2023 after selling out during the quarter.
  • Carnegie Investment Counsel sold 7,190 ARK Genomic Revolution ETF shares in Q4 2023, an estimated $200K.
  • Carnegie Investment Counsel first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 12 quarters.
  • Carnegie Investment Counsel's ARK Genomic Revolution ETF position peaked at $1.77M in Q3 2021.
  • 300 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2023.

Based on Carnegie Investment Counsel's 13F filing for Q4 2023, filed 30 Jan 2024.